XOMA Royalty Corp - Company Profile
Powered by 
All the sales intelligence you need on XOMA Royalty Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how XOMA Royalty Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with XOMA Royalty Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
XOMA Royalty Corporation (Xoma) is a biotech royalty aggregator. The company focuses on acquiring economic rights to future milestone and royalty payments from partnered therapeutic candidates. Its main activities involve building a portfolio through the acquisition of rights to future milestones, royalties, and commercial payments. Xoma's portfolio includes early to mid-stage clinical assets, primarily in Phase 1 and 2 development, as well as late-stage and commercial assets. The company's products and services are utilized by partners with expertise in drug development and commercialization, addressing unmet markets or offering therapeutic advantages. Xoma collaborates with partners such as Gossamer Bio, Chiesi Farmaceutici, and others to enhance its distribution network. It operates through its subsidiaries in Bermuda, the UK, and the US. Xoma is headquartered in Berkeley, California, the US.
Headquarters
United States of America
Address
2200 Powell Street, Suite 310, Emeryville, California, 94608
Website
www.xoma.com
Telephone
1 510 2047200
No of Employees
14
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
XOMA (NASD)
Revenue (2024)
$52.1M
83.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
329.4%
(2024 vs 2023)
Market Cap*
$710.2M
Net Profit Margin (2024)
XYZ
225.3%
(2024 vs 2023)
* As of and is in US$
XOMA Royalty Corp premium industry data and analytics
Products and Services
| Products |
|---|
| Royalty |
| DSUVIA- Acute pain- Alora Pharmaceuticals |
| ficlatuzumab (AV-299)- HGF- AVEO Oncology |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Ownership Changes | In July, the company was acquired by Ligand Pharmaceuticals for US$739 million. |
| 2026 | Acquisitions/Mergers/Takeovers | In February, the company acquired Generation Bio, a biotechnology company. |
| 2025 | Acquisitions/Mergers/Takeovers | In November, the company acquired LAVA Therapeutics N.V. |
Competitor Comparison
| Key Parameters | XOMA Royalty Corp | Emergent BioSolutions Inc | EyePoint Inc | Precigen Inc | Osiris Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Emeryville | Gaithersburg | Watertown | Germantown | Timonium |
| State/Province | California | Maryland | Massachusetts | Maryland | Maryland |
| No. of Employees | 14 | 900 | 214 | 160 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jack L. Wyszomierski | Chairman | Executive Board | 2024 | 69 |
| Owen Hughes | Chief Executive Officer; Director | Executive Board | 2024 | 50 |
| Jeffrey Trigilio | Chief Financial Officer | Senior Management | 2026 | - |
| Brad Sitko | Chief Investment Officer | Senior Management | 2023 | 43 |
| Barbara Kosacz | Director | Non Executive Board | 2019 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer